Tarhini, A. A., Lee, S. J., Davar, D., Slingluff, C. L., Messina, J., Cohen, G. I., Wright, G. P., Poklepovic, A. S., Najjar, Y. G., Cintolo-Gonzalez, J. A., Lutzky, J., Gaughan, E. M., Mehnert, J. M., Wolchok, J. D., Kirkwood, J. M. (2025). A phase II randomized study of neoadjuvant pembrolizumab (P) alone or in combination with vidutolimod (V) in high-risk resectable melanoma: ECOG-ACRIN EA6194.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.17_suppl.lba9505